Evidence is growing that IgE could be involved in autoimmune diseases such as in bullous pemphigoid (BP) or systemic lupus erythematosus (SLE), which has sparked the evaluation of omalizumab in those conditions [61,62,63]. The gene discussed is IGHE; the disease is systemic lupus erythematosus.